INCYTE CORP (INCY) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $33.3M sold). Latest close $117.80 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.
Baker Bros. Advisors · Sound Shore · Dodge & Cox Funds — 3 tracked funds hold INCY. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 17 sales ($33.3M). Insider trading
ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) · VSE CORP (VSEC) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Baker Bros. Advisors | 17.48% | 30,762,330 | ADDED (+0.1%) Q3 filed Nov 16 |
| Sound Shore | 2.64% | 757,723 | TRIMMED (-1.3%) Q3 filed Nov 6 |
| Dodge & Cox Funds | 0.71% | 11,957,326 | TRIMMED (-2.4%) Q3 filed Nov 13 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +4.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 857 of 8,857 filers |
| Long-only filers among them | 852 |
| Change vs 2026 Q1 | +57 net · 772 entered · 715 exited |
| Shares reported, all filers | 201,371,341 |
| Reported value, all filers | $21.8B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Services-Commercial Physical & Biological Research (SIC 8731) |
| Revenue · FY2025 | $5.1B |
| Net income · FY2025 | $1.3B |
| Total assets · FY2025 | $7.0B |
| Shares outstanding | 203,832,492 |
| Market cap (at latest close) | $24.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 22, 2026.
| Shares short · Oct 15, 2026 | 10,025,354 |
| Share of shares outstanding | 4.92% |
| Days to cover | 5.32 |
Shares short at recent settlements — Jul 31, 2026: 10.2M · Aug 14, 2026: 9.4M · Aug 31, 2026: 9.4M · Sep 15, 2026: 10.0M · Sep 30, 2026: 10.0M · Oct 15, 2026: 10.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 22, 2026.
| Shares failed to deliver · Oct 14, 2026 | 6 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 12K · Aug 14, 2026: 0 · Aug 31, 2026: 7 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 6.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 22, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 17 sales by 4 insiders ($33.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | Sell | 576 | $121.98 | $70.3K | SEC filing |
| Nov 16, 2026 | CAGNONI PABLO J | President, Global Head of R&D | Sell | 877 | $121.98 | $107.0K | SEC filing |
| Nov 16, 2026 | CAGNONI PABLO J | President, Global Head of R&D | Sell | 1,765 | $120.46 | $212.6K | SEC filing |
| Nov 13, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Sell | 1,471 | $121.89 | $179.3K | SEC filing |
| Nov 13, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Sell | 2,200 | $120.44 | $265.0K | SEC filing |
| Nov 13, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Sell | 874 | $121.16 | $105.9K | SEC filing |
| Nov 13, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Sell | 3,700 | $120.33 | $445.2K | SEC filing |
| Nov 13, 2026 | Heeson Lee | EVP, Head of Incyte Intl | Sell | 2,449 | $121.13 | $296.7K | SEC filing |
| Nov 6, 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | Sell | 35,042 | $116.06 | $4.1M | SEC filing |
| Nov 6, 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | Sell | 22,336 | $117.14 | $2.6M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | PABLO CAGNONI | Officer | 23,218 | $2.8M | Sep 15, 2026 | SEC filing |
| Aug 19, 2026 | PABLO CAGNONI | Officer | 10,801 | $1.4M | Aug 19, 2026 | SEC filing |
| Aug 12, 2026 | PABLO CAGNONI | Officer | 10,803 | $1.3M | Aug 12, 2026 | SEC filing |
| Aug 5, 2026 | PABLO CAGNONI | Officer | 10,640 | $1.3M | Aug 5, 2026 | SEC filing |
| Aug 5, 2026 | PATRICK A MAYES | Officer | 2,207 | $273.6K | Aug 5, 2026 | SEC filing |
| Aug 3, 2026 | PATRICK A MAYES | Officer | 6,055 | $729.2K | Aug 3, 2026 | SEC filing |
| Jul 31, 2026 | PATRICK A MAYES | Officer | 41,899 | $5.0M | Jul 31, 2026 | SEC filing |
| Jul 31, 2026 | PABLO CAGNONI | Officer | 15,888 | $1.9M | Jul 31, 2026 | SEC filing |
| Jul 16, 2026 | STEVEN STEIN | Officer | 1,877 | $215.3K | Jul 16, 2026 | SEC filing |
| Jul 16, 2026 | MOHAMED ISSA | Officer | 1,093 | $125.7K | Jul 16, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| May 11, 2026 | SCHEDULE 13D/A | +20.1% (close May 12, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (May 12, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Dodge & Cox | SC 13G/A | 12,252,356 | 6.2% | Mar 31, 2026 | SEC filing |
| May 11, 2026 | Baker Bros. Advisors LP | SC 13D/A | 30,865,077 | 15.4% | May 7, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 12,591,630 | 6.3% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 10, 2026 | Baker Bros. Advisors LP | SC 13D/A | 30,852,922 | 15.5% | Feb 6, 2026 | SEC filing |
| Nov 10, 2025 | STATE STREET CORPORATION | SC 13G | 9,677,414 | 5.0% | Sep 30, 2025 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G/A | 15,242,171 | 7.8% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Services-Commercial Physical & Biological Research (SIC 8731). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 129 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Medicare/Medicaid (99), Health Issues (52), Copyright/Patent/Trademark (6).
Federal contracts: $452.4K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $292.7K |
| FY2022 | $-63.6K |
| FY2023 | $102.2K |
| FY2024 | $121.1K |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C26124N0749 | Department of Veterans Affairs | $119.6K | Jul 2, 2024 |
| 36C24121F0107 | Department of Veterans Affairs | $63.6K | Jan 19, 2021 |
| 36C24122F0150 | Department of Veterans Affairs | $25.5K | Apr 27, 2022 |
| 36C26124N0511 | Department of Veterans Affairs | $13.3K | Mar 18, 2024 |
| 36C26124N0408 | Department of Veterans Affairs | $13.3K | Jan 26, 2024 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Greenblatt Magic Formula — High earnings yield and high return on capital together
· O'Neil CAN SLIM — Explosive earnings growth leaders
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $5.1B · 5-yr revenue CAGR: 14.0% · Straight growth years: 14
· Graham — Current ratio: 3.32 · Straight profitable years: 5 · Debt ratio: 0.35 · Latest net income: $1.3B
· Greenblatt Magic Formula — Earnings yield: 6.8% · Return on capital: 35.7% · Combined rank: 85
· O'Neil CAN SLIM — 3-yr EPS growth: 61.6% · ROE: 24.9% · Latest revenue growth: 21.2%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 4.07 · Operating cash flow: $1.4B · Net income: $1.3B
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold INCY — ranked by lift, the co-holding pattern described in Methodology: ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) · VSE CORP (VSEC) · Genpact LTD (G) · PAYCHEX INC (PAYX) · Booz Allen Hamilton Holding Corp (BAH).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 13, 2026 | 8.01 Other Events | SEC filing |
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 31, 2026 | 8.01 Other Events | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ICON PLC (ICLR) · Track Record: how the signals scored · Practice timing on INCY
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.